We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Technique Reveals Earliest Signs of Genetic Mutations

By LabMedica International staff writers
Posted on 14 Jun 2024
Print article
Image: The Hairpin Duplex Enhanced Fidelity Sequencing (HiDEF-seq) could reveal the causes of mutations (Photo courtesy of Shutterstock)
Image: The Hairpin Duplex Enhanced Fidelity Sequencing (HiDEF-seq) could reveal the causes of mutations (Photo courtesy of Shutterstock)

Mutations are alterations in the molecular "letters" that constitute the DNA code, which serves as the blueprint for all living cells. While some of these changes may be inconsequential, others can lead to serious diseases, including cancer. Now, a new study has introduced a groundbreaking technique that can accurately identify early molecular changes in the DNA code that precede mutations. This new method could enhance our understanding of the fundamental causes of mutations in both healthy and cancerous cells, as well as how genetic changes accumulate naturally in human cells as individuals age.

The technique, known as HiDEF-seq (Hairpin Duplex Enhanced Fidelity Sequencing), was developed by researchers at NYU Langone Health (New York, NY, USA), along with collaborators across North America and in Denmark. It focuses on resolving the initial stages of mutation occurring in DNA. DNA consists of two strands, each made up of molecular letters or bases: adenine (A), thymine (T), guanine (G), and cytosine (C). The bases on one strand pair specifically with those on the other, with A pairing with T and G pairing with C, which ensures the DNA code is replicated accurately and transmitted from one cell generation to the next. Notably, mutations are alterations that appear in the DNA on both strands; for example, a G-C base pair might mutate into an A-T base pair.

However, the researchers point out that most mutations originate from changes that occur in just one of the DNA strands, such as a mismatched G-T base pair. These single-strand changes, which previous testing methods could not precisely identify, may happen when a DNA strand is incorrectly copied during cell division or when a strand is damaged by heat or chemicals in the body. If these single-strand DNA changes are not repaired by the cell, they can become fixed and evolve into permanent double-strand mutations. The HiDEF-seq technique has demonstrated exceptional accuracy in detecting double-strand mutations, with an estimated error rate of only one in every 100 trillion base pairs analyzed. Importantly, HiDEF-seq can detect changes in the DNA code while they are still present on only one of the DNA strands before they change into permanent double-strand mutations.

"Our new HiDEF-seq sequencing technique allows us to see the earliest fingerprints of molecular changes in DNA when the changes are only in single strands of DNA," said senior study author Gilad Evrony, MD, PhD, a core member of the Center for Human Genetics & Genomics at NYU Grossman School of Medicine. "Our study lays the foundation for using the HiDEF-seq technique in future experiments to transform our understanding of how DNA damage and mutations arise. Our long-term goal is to use HiDEF-seq to create a comprehensive catalogue of single-strand DNA mismatch and damage patterns that will help explain the known double-strand mutation patterns. In the future, we hope to combine profiling of single-strand DNA lesions, as obtained from HiDEF-seq, with the lesions' resulting double-strand mutations to better understand and monitor the everyday effects on DNA from environmental exposures." The study was published in Nature on June 12, 2024.

Related Links:
NYU Grossman School of Medicine

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more